# Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

> **NCT02462538** · PHASE1,PHASE2 · TERMINATED · sponsor: **Arbeitsgemeinschaft medikamentoese Tumortherapie** · enrollment: 3 (actual)

## Conditions studied

- ALK+ Anaplastic Large Cell Lymphoma

## Interventions

- **DRUG:** Brentuximab vedotin
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT02462538
- **Lead sponsor:** Arbeitsgemeinschaft medikamentoese Tumortherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11-03
- **Primary completion:** 2021-11-03
- **Final completion:** 2021-11-03
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Due to slow recruitment, recruitment of new patients was stopped, FU was completed for enrolled patients
- **Last updated:** 2022-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02462538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02462538, "Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02462538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*